secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2022-03-07T23:59:59+00:00
Accession:  0000950170-22-002960
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio doses first healthy volunteers in Phase 1 study of RLYB116; data expected H2 2022
--------------------------------------------------------------------------------

- First healthy volunteers dosed in Phase 1 study of RLYB116.
- Single dose safety, PK, and PD data expected in second half of 2022.
- Corporate presentation updated to reflect Phase 1 milestone and data timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022002960/0000950170-22-002960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022002960/rlyb-20220307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer